To hopefully engage a broad audience I look foward to presenting on our collaborative work, with the University of Missouri, using radiolabeled antibodies for immune monitoring and therapy targeting immunosuppressive myeloid cells. The focus will then transition to unpublished work recently resubmitted to STM using T-cell clonal expansion as a metric in Diagnosis of pediatric brain tumor diagnosis and for developing T-cell-based Therapy.  

About the Speaker

Dr. Kohanbash is currently an Assistant professor of neurological surgery, immunology, and bioengineering at the University of Pittsburgh and Director of the pediatric neurosurgery immunooncology laboratory. He joined the faculty of the Department of Neurological Surgery at UPMC Children’s Hospital of Pittsburgh in January of 2017 Dr. Kohanbash graduated from the University of Pittsburgh in 2007 with a bachelor of science honors degree in neuroscience, specializing in neurodegenerative diseases. He then earned his masters of science degree in infectious diseases and microbiology in 2009, and a doctorate in philosophy in 2012, both from the University of Pittsburgh Graduate School of Public Health. While there, he identified novel pathways of immunosuppression in gliomas and participated in multiple phase I/II immunotherapy clinical trials Dr. Kohanbash subsequently completed a post-doctoral fellowship in the University of Pittsburgh Department of Neurological Surgery in 2014. He continued his training as a postdoctoral fellow at the University of California, San Francisco (UCSF) Department of Neurological Surgery. While at UCSF, Dr. Kohanbash was privileged to complete a prestigious T32 training program in translational brain tumor research.